{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-016502","form_type":"8-K","ticker":"BFRI","cik":"0001858685","company_name":"Biofrontera Inc.","filed_at":"2023-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.315695+00:00","generated_at":"2026-06-15T02:49:06.092676+00:00","sec_items":["2.02","5.02","7.01","9.01"],"event_type":"leadership","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Biofrontera CEO Monaco resigns; Luebbert takes over; Q1 revenue $8.7M, net loss $7.5M","bullets":["CEO Erica Monaco resigning; Executive Chairman Hermann Luebbert to assume CEO role; effective near term.","Q1 2023 revenue $8.7M, down 11% YoY due to prior-year buy-in; net loss $7.5M vs net income $5.6M.","Q1 2023 net loss per share $(0.28) vs prior-year EPS $0.32; adjusted EBITDA -$4.0M.","Cash and cash equivalents $13.5M as of March 31, 2023, down from $17.2M Dec 31, 2022.","Affirms full-year 2023 revenue growth at least 25% vs 2022; expects cash flow positive within two years."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-016502","json":"https://secwatch.observer/filing/0001493152-23-016502.json","markdown":"https://secwatch.observer/filing/0001493152-23-016502.md","text":"https://secwatch.observer/filing/0001493152-23-016502.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858685/000149315223016502/0001493152-23-016502-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858685/000149315223016502/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T02:49:06.092676+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2cc5cb7db083a36be66ed1fe9a159fa67d647286","claim":"Biofrontera Inc. reported first quarter ended March 31, 2023 results: revenue $8.7 million, EPS $(0.28) per share. Guidance reaffirmed.","evidence_excerpt":"Total revenues for the first quarter of 2023 were $8.7 million compared with $9.8 million for the first quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1858685/000149315223016502/0001493152-23-016502-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Revenue","value":"$8.7 million"},{"label":"EPS","value":"$(0.28) per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"9d0f3b1222","claim":"Erica Monaco departed as Chief Executive Officer at Biofrontera Inc..","evidence_excerpt":"Erica Monaco, Chief Executive Officer of the Company notified the Company’s Board of Directors that she intends to resign from the Company to pursue other opportunities.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1858685/000149315223016502/0001493152-23-016502-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resign"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}